Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study

Matsuoka, H; Iwase, S; Miyaji, T; Kawaguchi, T; Ariyoshi, K; Oyamada, S; Satomi, E; Ishiki, H; Hasuo, H; Sakuma, H; Tokoro, A; Matsuda, Y; Tahara, K; Otani, H; Ohtake, Y; Tsukuura, H; Matsumoto, Y; Hasegawa, Y; Kataoka, Y; Otsuka, M; Sakai, K; Nakura, M; Morita, T; Yamaguchi, T; Koyama, A

Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study

Matsuoka, H Iwase, S Miyaji, T Kawaguchi, T Ariyoshi, K Oyamada, S Satomi, E Ishiki, H Hasuo, H Sakuma, H Tokoro, A Matsuda, Y Tahara, K Otani, H Ohtake, Y Tsukuura, H Matsumoto, Y Hasegawa, Y Kataoka, Y Otsuka, M Sakai, K Nakura, M Morita, T Yamaguchi, T Koyama, A

Permalink

Publisher:: Springer Science and Business Media LLC
Publication Type:: Journal Article
Citation:: Supportive Care in Cancer, 2020, 28, (6), pp. 2931-2939
Issue Date:: 2020

Closed Access

	Filename	Description	Size
	Matsuoka2020_Article_PredictorsOfDuloxetineResponse.pdf	Published version	459.79 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Matsuoka, H
dc.contributor.author	Iwase, S
dc.contributor.author	Miyaji, T
dc.contributor.author	Kawaguchi, T
dc.contributor.author	Ariyoshi, K
dc.contributor.author	Oyamada, S
dc.contributor.author	Satomi, E
dc.contributor.author	Ishiki, H
dc.contributor.author	Hasuo, H
dc.contributor.author	Sakuma, H
dc.contributor.author	Tokoro, A
dc.contributor.author	Matsuda, Y
dc.contributor.author	Tahara, K
dc.contributor.author	Otani, H
dc.contributor.author	Ohtake, Y
dc.contributor.author	Tsukuura, H
dc.contributor.author	Matsumoto, Y
dc.contributor.author	Hasegawa, Y
dc.contributor.author	Kataoka, Y
dc.contributor.author	Otsuka, M
dc.contributor.author	Sakai, K
dc.contributor.author	Nakura, M
dc.contributor.author	Morita, T
dc.contributor.author	Yamaguchi, T
dc.contributor.author	Koyama, A
dc.date.accessioned	2020-09-02T01:39:35Z
dc.date.available	2019-10-16
dc.date.available	2020-09-02T01:39:35Z
dc.date.issued	2020
dc.identifier.citation	Supportive Care in Cancer, 2020, 28, (6), pp. 2931-2939
dc.identifier.issn	0941-4355
dc.identifier.issn	1433-7339
dc.identifier.uri	http://hdl.handle.net/10453/142487
dc.description.abstract	© 2019, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. Methods: Patients (N = 70) with CNP unresponsive to or intolerant of opioid–pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill pain questionnaire 2 (SF-MPQ-2) as independent variables. Results: Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). Conclusion: Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Springer Science and Business Media LLC
dc.relation.ispartof	Supportive Care in Cancer
dc.relation.isbasedon	10.1007/s00520-019-05138-9
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Neuralgia
dc.subject.mesh	Placebos
dc.subject.mesh	Pain Measurement
dc.subject.mesh	Prognosis
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Japan
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Chronic Pain
dc.subject.mesh	Duloxetine Hydrochloride
dc.subject.mesh	Cancer Pain
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Cancer Pain
dc.subject.mesh	Chronic Pain
dc.subject.mesh	Double-Blind Method
dc.subject.mesh	Duloxetine Hydrochloride
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	Japan
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	Neoplasms
dc.subject.mesh	Neuralgia
dc.subject.mesh	Pain Measurement
dc.subject.mesh	Placebos
dc.subject.mesh	Prognosis
dc.subject.mesh	Treatment Outcome
dc.title	Predictors of duloxetine response in patients with neuropathic cancer pain: a secondary analysis of a randomized controlled trial—JORTC-PAL08 (DIRECT) study
dc.type	Journal Article
utslib.citation.volume	28
utslib.location.activity	Germany
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	closed_access	*
pubs.consider-herdc	true
dc.date.updated	2020-09-02T01:39:28Z
pubs.issue	6
pubs.publication-status	Published
pubs.volume	28
utslib.citation.issue	6

Abstract:

© 2019, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: Duloxetine has some effect against cancer neuropathic pain (CNP); however, predictors of duloxetine response are unclear. This study sought to identify predictors of duloxetine response in patients with CNP. Methods: Patients (N = 70) with CNP unresponsive to or intolerant of opioid–pregabalin combination therapy, with a brief pain inventory-short form (BPI-SF) Item 5 score (average pain) ≥ 4, and with a total hospital anxiety and depression scale score < 20, were randomized to a duloxetine or a placebo group. Multiple linear regression analysis was conducted to identify predictors of duloxetine response as a secondary analysis with the change in the average pain score on day 10 from day 0 as the dependent variable, and the following five covariates; baseline (day 0) average pain score, baseline opioid dose, continuation/discontinuation of pregabalin, and items 20 and 21 score of the short-form McGill pain questionnaire 2 (SF-MPQ-2) as independent variables. Results: Of the four domains (continuous pain, intermittent pain, neuropathic pain, and affective descriptors) score of SF-MPQ-2 on day 0, significant differences were observed in the neuropathic pain domain (p = 0.040) in change on the average pain between day 10 and day 0 in the duloxetine group. Multiple linear regression analysis revealed that patients with a high score for SF-MPQ-2 Item 21 (tingling pain) on day 0 had a significantly greater change in average pain between day 10 and day 0 (p = 0.046). Conclusion: Patients with a high score for SF-MPQ-2 Item 21 might benefit more from duloxetine.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/142487